Response to: 'Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'' by Perricone
et al
Ann Rheum Dis
.
2023 Apr;82(4):e82.
doi: 10.1136/annrheumdis-2021-219898.
Epub 2021 Jan 28.
Authors
Binita Shah
1
2
,
Aaron Z Reyes
3
,
Kelly A Hu
3
,
Jacob Teperman
3
,
Theresa L Wampler Muskardin
4
,
Jean-Claude Tardif
5
,
Michael H Pillinger
6
7
Affiliations
1
Cardiology, New York University Grossman School of Medicine, New York, New York, USA.
2
Cardiology, VA New York Harbor Healthcare System, New York, New York, USA.
3
Medicine, New York University Grossman School of Medicinee, New York, New York, USA.
4
Rheumatology, New York University Grosssman School of Medicine, New York, New York, USA.
5
Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada.
6
Rheumatology, New York University Grosssman School of Medicine, New York, New York, USA
[email protected]
.
7
Rheumatology, VA New York Harbor Healthcare System, New York, New York, USA.
PMID:
33509798
DOI:
10.1136/annrheumdis-2021-219898
No abstract available
Keywords:
COVID-19; inflammation; therapeutics.
Publication types
Letter
Comment
MeSH terms
Anti-Inflammatory Agents
COVID-19*
Colchicine / therapeutic use
Humans
SARS-CoV-2
Substances
Colchicine
Anti-Inflammatory Agents